<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
ESC MEDICAL SYSTEMS LTD.
- --------------------------------------------------------------------------------
(Name of Issuer)
Ordinary Shares, NIS 0.10 par value per Share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
M40868107
- --------------------------------------------------------------------------------
(CUSIP Number)
Edward Klimerman, Esq.
Rubin Baum Levin Constant & Friedman
30 Rockefeller Plaza, 29th Floor
New York, New York 10112
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
March 22, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box. |_|
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7(b) for
other parties to whom copies are to be sent.
<PAGE> 2
SCHEDULE D
CUSIP NO. Page 2 of 13
M40868107
- -------------------------------- --------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Arie Genger
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) /x/
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC, PF, OO
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States and Israel
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 99,210(1)(3)
SHARES --------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER 2,317,062(2)(3)
OWNED BY --------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER 99,210(1)(3)
REPORTING --------------------------------------------------
PERSON 10 SHARED DISPOSITIVE POWER 2,317,062(2)(3)
WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,416,272(1)(2)(3)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.3%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
(1)Includes 40,000 shares owned by a trust for the benefit of a minor child of a
third party of which Mr. Genger is sole trustee, as to which Mr. Genger
disclaims beneficial ownership.
(2)Includes 4,000 shares beneficially owned by Mr. Genger's spouse, as to which
he disclaims beneficial ownership.
(3)Does not include 3,000 shares beneficially owned by a trust for a minor child
of Mr. Genger, as to which Mr. Genger has no voting or investment control.
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE> 3
SCHEDULE D
CUSIP NO. Page 3 of 13
M40868107
- -------------------------------- --------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
TPR Investment Associates, Inc.
(I.R.S. Employer Identification No. 13-3506464)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) /x/
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC, OO
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER -0-
SHARES --------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER 2,313,062
OWNED BY --------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER -0-
REPORTING --------------------------------------------------
PERSON 10 SHARED DISPOSITIVE POWER 2,313,062
WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,313,062
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.9%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE> 4
SCHEDULE D
CUSIP NO. Page 4 of 13
M40868107
- -------------------------------- --------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Trans-Resources, Inc.
(I.R.S. Employer Identification No. 36-2729497)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) /x/
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC, OO
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER -0-
SHARES --------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER 2,115,562
OWNED BY --------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER -0-
REPORTING --------------------------------------------------
PERSON 10 SHARED DISPOSITIVE POWER 2,115,562
WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,115,562
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.1%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE> 5
SCHEDULE D
CUSIP NO. Page 5 of 13
M40868107
- -------------------------------- --------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Haifa Chemicals Holdings Ltd.
(Israeli corporation with no United States I.R.S. Identification No.)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) /x/
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC, OO
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Israel
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER -0-
SHARES --------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER 682,312
OWNED BY --------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER -0-
REPORTING --------------------------------------------------
PERSON 10 SHARED DISPOSITIVE POWER 682,312
WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
682,312
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.6%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE> 6
SCHEDULE D
CUSIP NO. Page 6 of 13
M40868107
- -------------------------------- --------------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Thomas G. Hardy
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) /x/
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
PF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Australla
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 54,250
SHARES --------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER -0-
OWNED BY --------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER 54,250
REPORTING --------------------------------------------------
PERSON 10 SHARED DISPOSITIVE POWER -0-
WITH
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
54,250
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
/ /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.2%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE AND THE SIGNATURE ATTESTATION.
<PAGE> 7
This Amendment No. 2 (the "Amendment") amends the Schedule 13D filed on
October 9, 1998, as previously amended and restated by Amendment No. 1 thereto
filed on March 12, 1999 (the "Schedule 13D"), on behalf of Mr. Arie Genger
("Genger"), TPR Investment Associates, Inc., a Delaware corporation ("TPR"),
TPR's subsidiary, Trans-Resources, Inc., a Delaware corporation ("TRI"), TRI's
indirect subsidiary, Haifa Chemicals Holdings Ltd., a company incorporated in
the State of Israel ("HCH"; Genger and said corporations, all of which are
directly or indirectly controlled by Genger, being collectively called the "TRI
Entities"), and Mr. Thomas G. Hardy ("Hardy"; Hardy and the TRI Entities being
collectively called the "Reporting Persons") with respect to the Ordinary
Shares, par value NIS 0.10 per share (the "Shares"), of ESC Medical Systems
Ltd., a company incorporated in the State of Israel (the "Issuer"). The
Reporting Persons are filing this Amendment to update the information with
respect to the Reporting Persons' purposes and intentions with respect to the
Shares and to update the Schedule 13D in certain other respects. As previously
discussed in the Schedule 13D, Genger has reached an understanding with Mr.
Barnard J. Gottstein ("BG") (who had previously filed his own Schedule 13D) to
work together to achieve certain of these purposes, with the result that the
Reporting Persons may be deemed to have formed a "group" with BG. The Reporting
Persons expressly disclaim any such "group" membership between the Reporting
Persons and BG. Although Hardy is one of the Reporting Persons, the TRI Entities
and Hardy expressly disclaim any "group" membership among the TRI Entities and
Hardy.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is hereby amended and supplemented as
follows:
Page 7 of 13
<PAGE> 8
See Item 5 hereof for certain information regarding purchases of Shares
by directors and executive officers of TRI.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended and supplemented as
follows:
On March 22, 1999, the legal representative of Genger and BG sent a
letter to the legal representative of the Issuer, advising the Issuer of the
names of the directors that have been proposed by Genger and BG to replace two
management directors (other than Dr. Eckhouse) and one non-management director
selected by the Issuer's present Board of Directors (other than Hardy). A copy
of such letter is attached hereto as Exhibit 6.
Other than as described above and as previously described in the
Schedule 13D, the Reporting Persons do not have any present plans or proposals
which relate to or would result in (although they reserve the right to develop
such plans or proposals) any transaction, change or event specified in clauses
(a) through (j) of Item 4 of the form of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Schedule 13D is hereby amended and supplemented as
follows:
The percentages set forth in each Reporting Person's separate cover
page have been recalculated to be based upon 26,027,000 Shares outstanding,
which represents the weighted average number of Shares outstanding during the
three-month and twelve-month periods ended December 31, 1998, as reported in the
Issuer's Form 6-K, which was filed with the Securities and Exchange Commission
on February 16, 1999. Reference is made to the information contained in Items
7-13 of each Reporting Person's separate cover page for the aggregate number and
percentage of total outstanding Shares beneficially owned by each Reporting
Person.
Page 8 of 13
<PAGE> 9
To the knowledge of the Reporting Persons, no director or executive
officer of TPR, TRI or HCH other than Genger and Hardy is the beneficial owner
of any Shares, except for Sash A. Spencer, director of TRI, who owns 11,000
Shares (purchased at an aggregate cost of approximately $71,500 from personal
funds); Gabriel Politzer, Senior Vice President of TRI, who owns 2,950 Shares
(purchased at an aggregate cost of $20,000 from personal funds); and Martin A.
Coleman, director of TRI, who owns 2,000 Shares (purchased at an aggregate cost
of $18,000 from personal funds) and $100,000 principal amount of the Issuer's 6%
Convertible Subordinated Notes due 2002 (purchased at a cost of $70,000 from
personal funds) which are convertible into Shares at an initial conversion price
of $46.55 per Share, subject to adjustment.
Item 7. Materials to be Filed as Exhibits.
Exhibit 6: Letter, dated March 22, 1999, from the legal representative
of Genger and BG to the legal representative of the Issuer.
SIGNATURES
After reasonable inquiry and to the best of the undersigned's knowledge
and belief, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Dated: March 22, 1999
/s/ Arie Genger
---------------
Arie Genger
TPR INVESTMENT ASSOCIATES, INC.
By:/s/ Arie Genger
---------------
Arie Genger,
President
Page 9 of 13
<PAGE> 10
TRANS-RESOURCES, INC.
By:/s/ Arie Genger
------------------
Arie Genger,
Chairman of the Board
HAIFA CHEMICALS HOLDINGS LTD.(1)
By:/s/ Arie Genger
------------------
Arie Genger
/s/ Thomas G. Hardy
-------------------
Thomas G. Hardy
- --------
(1) pursuant to power of attorney
Page 10 of 13
<PAGE> 11
EXHIBIT INDEX
Exhibit
Number Title Page
6 Letter, dated March 22, 1999,
from Mr. Barnard J. Gottstein 12
and Mr. Arie Genger to the
Company
Page 11 of 13
<PAGE> 1
Exhibit 6
March 22, 1999
VIA FACSIMILE
Mr. Gene Kleinhandler
Kleinhandler & Halevy
30 Kalisher Street
Tel Aviv, Israel 65257
Re: ESC Medical Systems Ltd. (the "Company")
----------------------------------------
Dear Gene:
As per your request today, attached please find the curricula vitae of
the four individuals proposed by Messrs. Genger and Gottstein as replacements
and/or additions to the restructured Board of Directors of the Company. As
previously proposed, three of these individuals would replace two management
directors (other than Dr. Eckhouse) and one non-management director selected by
the present Board (other than Mr. Hardy). The fourth nominee would be added as a
new director.
With respect to any previous acquaintances between Messrs. Genger or
Gottstein and any of the four nominees, we note that Mr. Genger first met Mr.
Friedman this past Monday and was very impressed with his accomplishments. Mr.
Dovrat, as his curriculum vitae indicates, is a very well known entity in Israel
with whom neither Messrs. Genger nor Gottstein have had any prior business
relationship. Both Messrs. Spencer and Tadmor are outside, independent directors
of TRI or its affiliated entities and neither is an employee of Mr. Genger or
any of his affiliates.
With the change in the composition of the Board as proposed above,
neither management, Mr. Gottstein nor Mr. Genger will control a majority of the
Board of Directors of the Company. Accordingly, we respectfully request the
Board's assent to the addition of the foregoing individuals to the restructured
Board as outlined above and further request that we receive the Board's reply
within 24 hours.
Very truly yours,
/s/ Joseph J. Giunta
JJG:C
cc: Barnard Gottstein
Arie Genger
Page 12 of 13
<PAGE> 2
List of Individuals Proposed by Messrs. Genger and Gottstein
(curricula vitae intentionally omitted)
1. Philip Friedman
2. Aharon Dovrat
3. S.A. Spencer
4. Professor Zehev Tadmor
Page 13 of 13
